Whitehawk Therapeutics Inc WHWK
News
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
